Women’s health
This Outlook takes a look at conditions that affect only women, or more women than men, as well as those with different symptoms in the sexes. It discusses how to meet the challenges in conducting research in patriarchal societies in Africa; explains why research on sexual arousal in women has finally become a priority; and questions whether girls are entering puberty earlier — and, if so, whether we should be worried.
Free full access
To read more on the effect of X chromosomes, visit nature.com, see: go.nature.com/2xm9luk
For more on the dearth of women in clinical trials, visit: go.nature.com/2yjnzIx
This Nature Outlook is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge financial support from Symbiomix Therapeutics, LLC. in producing this Outlook. The sponsor retains sole responsibility for the following messages.
Symbiomix (pronounced ‘sim-bye-OH-mix’) Therapeutics is a biopharmaceutical company bringing innovative medicines to market for common gynecological infections that can have serious health consequences. The company’s lead medicine is Solosec (secnidazole) 2 g oral granules, a potent, next-generation 5-nitroimidazole antibiotic. Solosec is the first and only single-dose oral treatment approved for bacterial vaginosis (BV) in adult women. BV is characterized by a decrease in beneficial microbiota and an increase in potentially deleterious bacteria in the vaginal fluid. Solosec is contraindicated in patients with a history of hypersensitivity to secnidazole or other ingredients in the formulation, or to other nitroimidazole derivatives.
Symbiomix Therapeutics was founded in 2012 by a team of experienced industry professionals and entrepreneurs committed to finding new solutions to enhance women’s health. The company, backed by three of the world’s leading healthcare venture capital firms—OrbiMed, F-Prime Capital Partners, and HBM Partners—is based in New Jersey, and has offices in Maryland and Connecticut.
Please visit https://symbiomix.com/ and follow us on LinkedIn and Twitter for more information.
